Pei focuses her practice on patent prosecution and patent portfolio development in the fields of biotechnology, molecular diagnostics, medical devices and pharmaceuticals. She has extensive experience in preparation and prosecution of U.S. and foreign patent applications relating to genes, proteins, enzymes, recombinant antibodies, microorganisms, medical diagnostics, blood products, cell matrices, tissue engineering, dietary and food supplements, cancer treatments, gene therapy, drug discovery and formulation, epigenetics, biopolymer, vaccine, and genomics.
Pei counsels clients ranging from private and public companies to non-profit academic institutions and hospitals on strategic IP portfolio development that aligns with their business objectives. She advises clients on IP matters including patentability, patent landscape and freedom-to-operate analyses, non-infringement and invalidity opinions, pre-litigation counselling and due diligence relating to research collaboration, technology transfer, licensing and acquisition.
Pei has more than 10 years of law firm and in-house experience as a patent agent and patent attorney. She also has more than 10 years of biological research experience as an instructor at Brigham and Women’s Hospital, a scientist at Harvard Medical School and a postdoctoral research associate and research assistant professor at University of Florida.
Pei received her J.D. from Suffolk University Law School and her Graduate Certificate in management from Harvard Extension School. She received her Ph.D. in cell and developmental biology from University of Florida, where she was a recipient of Graduate Research and Medical Guilds Research competition awards. She obtained her B.S. in biochemistry from Wuhan University in China.
Her research was presented in international scientific conferences and published in scientific journals such as Nucleic Acids Research, Journal of Virology, Gene, Molecular and Cellular Biology and Journal of Biological Chemistry. She has also written newsletter articles relating to U.S. and China IP law and practices. She is fluent in Mandarin Chinese.